OptiBio Co., Ltd. is a South Korean in-vitro diagnostics (IVD) company focused in researching, developing, and
manufacturing cutting edge fluorescence immunoassay (FIA) solutions to enhance and progress quality healthcare access globally. In 2020, OptiBio was selected by a research fund sponsored by the Bill Melinda Gates foundation for its unique and dedicated approach to immunoassay. OptiBio's fundamental approach of integrating in-house capabilities allows OptiBio to constantly improve its product performance, customize its solutions based on client feedback, develop new test parameters, and respond to changing market needs. OptiBio will continue to create, improve, and innovate world class diagnostic solutions in the field of fluorescence immunoassay and point-of-care testing (POCT). Through this, we aim to ultimately transform medical diagnosis into a universally available right.